Resources

Poolbeg Pharma will act as the lead business partner, alongside Johnson & Johnson and other partners, on The University of Manchester and The Christie NHS Foundation Trust research programme which will facilitate wider research into cancer immunotherapy-induced CRS and the safer delivery of these treatments.

BIA thought leadership takes centre stage with two key reports published: last week saw the release of 'From innovation to impact: unlocking patient access to innovative rare disease medicines', and today 'UK cell and gene therapy: driving efficiencies and innovation' celebrates real-world UK success.

Meet the newly elected BIA Board members bringing fresh expertise to shape the future of life sciences.

Enedra Therapeutics appoints Adrian Ibrahim, PhD, MBA, as its new Chief Executive Officer. Dr Ibrahim will also join the Company’s Board of Directors.

Our latest report demonstrates the real-world success and scalable manufacturing available in the UK’s globally competitive ecosystem.

Just one month after launch, five early-stage science companies have moved into the Leap incubator lab space at ARC West London. The first cohort of innovators joining Leap includes: Solveteq, Reseda Life Sciences, Tachmed, IgEDAPT, and Sea2Carbon.

In this blog, Ethan Almond, Content & Communications Executive at BIA, explores the influence of the BIA’s bioProcessUK conference. The 22nd edition highlighted the UK’s leadership in bioprocessing.

The BioIndustry Association (BIA) released From Innovation to Impact: Unlocking Patient Access to Innovative Rare Disease Medicines, calling for new pathway to give UK patients access to innovative rare disease medicines.

IRCA Group, a global leader in high-quality food ingredients, has signed a lease at Pioneer Group’s new food and beverage incubator, Gastronomica at Colworth Science Park in Bedfordshire.

Brainomix has published a prospective real-world study demonstrating that its AI imaging platform, Brainomix 360 Stroke, significantly increased rates of endovascular thrombectomy (EVT) treatment.

BioPartner UK is delighted to announce the appointment of Nathalie Huther to its Advisory Board.

More than 110,000 people in the UK live with a muscle-wasting condition which gradually damages the way their muscles work. Over time, it stops them from living everyday life. In some cases, lives will be cut short. Through this partnership, the BIA will leverage the network it has fostered in the UK life sciences and biotech sector to support those affected by muscle-wasting conditions.

NRG Therapeutics, an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to announce expansion of its team with the appointment of Paul Thompson PhD as Chief Development Officer (CDO).

Autolus Therapeutics plc, an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the National Institute for Health and Care Excellence (NICE) has published draft guidance recommending AUCATZYL® (obecabtagene autoleucel, or “obe-cel”) for use in the National Health Service (NHS) in England and Wales as a treatment option for adult patients (≥26 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).

Hot off the press  – the UK-US pharma deal is announced, plus key policy changes impacting how NICE evaluates cost-effectiveness. Last week delivered bucketloads for our sector – and we are still unpicking it...

eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Royal Free London NHS Foundation Trust, through its Cell and Vector Innovation Centre (CVIC), have entered a strategic collaboration to build a seamless, scalable pathway for cell and gene therapy development and manufacturing in the UK.

Novo Nordisk announced the submission of a sNDA to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg, to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity. Under the CNPV expedited program, review is expected within 1–2 months following the FDA’s acceptance of the filing.